The Role of Estrogen Signaling Pathway and Targeted Therapy Exploration in Urological Tumors.

Although the primary endpoint, investigator-assessed progression-free survival (INV-PFS), did not reach statistical significance, giredestrant showed consistent therapeutic benefits across key subgroups, with higher response and clinical benefit rates observed among patients with ESR1-mutant tumors 144 .

also in 111,027 other papers